Alpha cognition strengthens its leadership team with appointment of robert wills to board of directors and announces departure of existing director john havens

Vancouver & dallas--(business wire)--alpha cognition inc. (nasdaq: acog) (“alpha cognition”, or the “company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of robert wills, ph.d., to its board of directors, effective immediately april 7, 2025. dr. wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate str.
ACOG Ratings Summary
ACOG Quant Ranking